Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY4178256 in Healthy Participants
NCT07698210Phase 1Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2026
- Primary completion
- Mar 2028
- Countries
- 1
01
Overview
Phase 1, randomised trial of LY4178256 (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration at Day 197. Started Jul 2026; status: recruiting.
02
Drugs
LY4178256
Beyond the preview
Go deeper on NCT07698210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07698210.